Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6452W HIGH $2.38
Volume
265.68 K
Value Traded
2.74 M
Short % Float
7.58%
Days to Cover
10.8
-2.33%Week
-26.23%1 Month
-31.87%3 Month
-40.68%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
283.29 M
EPS (TTM)
-0.70
P/E Ratio
-
Ent. Value
386.42 M
Total Shares
423.04 M
Float Shares
417.21 M
Insiders
0.56%
Institutions
7.86%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
CGC Catalyst Timeline
Dated clinical, regulatory and corporate events for Canopy Growth Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Canopy Growth Corporation
385Total events
2Upcoming
103Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Manufacturing MilestoneCMC / Inspection
Kincardine facility received renewed EU GMP certification
▲Product LaunchPost-Market
Expansion of Frosted Flyers infused pre-roll lineup in Canada with three new 8-pack variety formats and first bundle pack
▲Product LaunchTweedPost-Market
Relaunch of Tweed brand in Germany with MTL Cannabis strain lineup
▲Product LaunchPost-Market
Launch of Clarity, Unwind, and Daily Relief 90-pack softgel formats
▲Product LaunchPost-Market
Launch of Daily Relief higher-dose 30-pack and Nighttime Relief 90-pack
▲Debt Royalty FinancingCorporate
Term Loan prepayment of US$15M on or prior to March 31, 2026
▲Debt Royalty FinancingCorporate
Canopy Growth exchanges C$96.4M existing convertible debentures for new debentures, cash, shares, and warrants
◆AcquisitionCorporate
Acquisition of MTL Cannabis remains on track to close in current quarter
▲Debt Royalty FinancingCorporate
Term Loan prepayment of US$10M on or prior to December 31, 2025
▲Timing GuidanceVEAZYPresentation
Expects full quarter of VEAZY sales to support sequential growth in Storz & Bickel net revenue in Q3 FY2026
▲Going ConcernCorporate
Conditions that raised substantial doubt about going concern have been resolved
●Management ChangeCorporate
Appointment of Shan Atkins to Board of Directors effective August 6, 2025
▲Partnership / LicenseCorporate
Acreage Financing Consent obtained for additional US$22M funding
◆Timing GuidancePresentation
Expect to achieve positive Adjusted EBITDA on a consolidated basis in second half of fiscal year 2025
◆Management ChangeCorporate
CEO David Klein to retire at end of fiscal year ending March 31, 2025
◆Debt Royalty FinancingCorporate
Option to make additional US$100 million prepayment by March 31, 2025, which would extend maturity to September 18, 2027
◆Timing GuidancePresentation
Call Right and Put Right exercisable for Rolling Interest at highest price
◆Timing GuidancePresentation
Call Right exercise deadline for Rolling Interest (higher price)
▲Product LaunchPost-Market
Launch of new Storz & Bickel vaporizer expected in second half of calendar year 2025
▲Product LaunchPost-Market
Jetty expected to launch new solventless All-In-One vapes in New York
▲Product LaunchPost-Market
Launch of innovative infused pre-roll joint product in adult-use and medical channels
▲Debt Royalty FinancingCorporate
Early prepayment of US$100 million on senior secured term loan at discounted price of US$97.5 million
◆Partnership / LicenseCorporate
Wana and Jetty acquisitions expected to close in first half of FY2025
Past FDA Catalysts and PDUFA Decisions
How CGC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 94%
Micro Cap(rank 634 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CHI-202, CHI-101 UnknownCompletedNCT05026164 | Delayed Onset Muscle Soreness (DOMS) | Phase 2 | COMPLETED | 40 | Feb 4, 2022 | ||||||
| CBN and CBD UnknownCompletedNCT05839964 | Undisclosed | Phase 1/2 | COMPLETED | 301 | Dec 6, 2022 | ||||||
| THCv UnknownCompletedNCT05210634 | Undisclosed | Phase 1 | COMPLETED | 21 | May 6, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every CGC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ATKINS M SHANDirector | Sell | -3,096 143,421 held | $0.93 | 09/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CGC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CGC for Q2 2026. | ||||
Ownership Trends
CGC Short Interest
Shares sold short, counted twice a month.
7.58%
Short % of Float
of tradable shares sold short
31.6M
Shares Sold Short
+16.1% vs prior count
10.8 Very high
Days to Cover
trading days of normal volume to buy every short share back
2.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CGC ranks across every disease it competes in
Competitive Position is a premium feature
See how CGC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCGC News
-CGC
Oct 26, 2026Canopy Growth Announces Results of 2026 Annual General and Special Meeting of Shareholders
Canopy Growth Corporation announced the results of its annual general and special meeting held on September 25, 2026, and reconvened on October 23, 2026. A total of 154,837,897 common shares were voted, representing 36.60% of the total shares. This reflects significant shareholder engagement in the company's governance.
Read more →-CGC
Oct 22, 2026Canopy Growth to Report Second Quarter Fiscal 2027 Financial Results on November 6, 2026
Canopy Growth Corporation will announce its financial results for the second quarter of fiscal 2027 on November 6, 2026. The results will cover the period ending September 30, 2026. An audio webcast featuring CEO Luc Mongeau and CFO Tom Stewart will follow the announcement.
Read more →-CGC
Oct 13, 2026Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower
Canopy Growth Corporation announced that its Smiths Falls facility has received EU GMP certification, making it the only site in Canada to combine softgel manufacturing with primary packaging of softgels, oral liquids, and dried cannabis flower. This certification enhances the company's ability to meet international quality standards and expand its market reach.
Read more →-CGC
Sep 28, 2026Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany
Canopy Growth Corporation has appointed Sebastian Blöte as the new Country Manager for Germany, effective October 1, 2026. In this role, Blöte will oversee the company's commercial strategy in Germany, aiming to expand sales and improve market execution. This move reflects Canopy Growth's commitment to strengthening its position in the German cannabis market.
Read more →-CGC
Sep 22, 2026Canopy Growth Expands European Medical Cannabis Supply Into the UK
Canopy Growth Corporation has announced its expansion into the UK market by supplying four Canadian-grown medical cannabis flower strains. This move marks a significant step in enhancing its international cannabis business. The company aims to improve patient access to medical cannabis in the UK, further solidifying its global presence.
Read more →-CGC
Sep 14, 2026Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline
Canopy Growth Corporation has issued a reminder to its shareholders to vote ahead of the Annual General and Special Meeting scheduled for September 25, 2026. Shareholders are encouraged to submit their votes by 1:00 p.m. ET to ensure their participation is counted. This initiative reflects the company's commitment to shareholder engagement.
Read more →-CGC
Sep 8, 2026Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations
Canopy Growth Corporation has announced an expansion of its medical cannabis portfolio in Australia. This includes the introduction of two new product formats and new formulations within its existing oil and softgel ranges. The expansion is part of Canopy's ongoing commitment to improving lives through cannabis.
Read more →-CGC
Aug 17, 2026Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now
Canopy Growth Corporation has mailed its proxy materials and fiscal 2026 annual report to shareholders for the upcoming Annual General and Special Meeting. The company urges shareholders to participate in the voting process. This initiative reflects Canopy Growth's commitment to transparency and shareholder engagement.
Read more →-CGC
Aug 14, 2026Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows
Canopy Growth Corporation has announced that its Kincardine cultivation facility has received renewed EU GMP certification. This certification is crucial for the company's expansion in the European medical cannabis market. The renewed status underscores Canopy's commitment to maintaining high manufacturing standards in its operations.
Read more →-CGC
Jul 24, 2026Canopy Growth to Report First Quarter Fiscal 2027 Financial Results on August 7, 2026
Canopy Growth Corporation has announced that it will report its financial results for the first quarter of fiscal 2027 on August 7, 2026. The company will hold a conference call at 10:00 AM ET to discuss these results. This proactive approach aims to keep investors informed.
Read more →-CGC
Jul 21, 2026Canopy Growth Announces Participation at Upcoming Canaccord Genuity Growth Conference
Canopy Growth Corporation announced its participation in the Canaccord Genuity Growth Conference scheduled for August 2026. CEO Luc Mongeau will present on August 11 at 12:00 p.m., with the presentation available via live webcast and archived for 180 days. This event underscores the company's commitment to investor engagement.
Read more →-CGC
Jun 15, 2026Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis
Canopy Growth has reported its financial results for the fourth quarter and fiscal year 2026, highlighting a net revenue growth of 27% in Canada’s medical cannabis sector and 68% growth in international markets. The report reflects the company's ongoing efforts to expand its market presence and improve financial performance. Further details on operational strategies and future outlook were not disclosed.
Read more →-CGC
Jun 8, 2026Canopy Growth Announces Claybourne’s Frosted Flyers Wins ‘Best Infused Pre-Roll' at 2026 Grow Up Awards
Canopy Growth Corporation announced that its Claybourne's Frosted Flyers Variety Pack won the Best Infused Pre-Roll award at the 2026 Grow Up Awards. The company is expanding its Frosted Flyers lineup with new variety packs to cater to consumer preferences. This expansion aims to enhance market share and provide more options for consumers this summer.
Read more →-CGC
May 29, 2026Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
Canopy Growth has announced the relaunch of its Tweed brand in Germany, introducing a new lineup of MTL cannabis strains. This marks the company's first international release following its recent acquisition. The move is seen as a strategic expansion into the European market, aiming to enhance brand visibility and product offerings.
Read more →-CGC
May 15, 2026Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on ON - May 15, 2026 - Canopy Growth Corporation ("Canopy Growth"
Canopy Growth Corporation (CGC) announced its plans to release financial results for the fourth quarter and fiscal year ended March 31, 2026, on June 15, 2026. The company also revealed that it will restate financial results for the years ending March 31, 2025, and March 31, 2024, due to a technical non-cash accounting error. This reclassification of share-settled warrants has led to the decision to file for a management cease trade order involving certain company directors until the refiling is completed. Despite these issues, Canopy Growth emphasized that the underlying business performance remains unaffected.
Read more →-CGC
May 7, 2026Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options
Canopy Growth Corporation and Spectrum Therapeutics have expanded their Minor Cannabinoid softgel lineup by introducing new 30 and 90-pack formats along with enhanced dosing options. This expansion aims to improve patient access and reflects the companies' commitment to addressing patient needs. The new formulations are designed to support both daytime and nighttime use, enhancing convenience and affordability for patients.
Read more →-CGC
Apr 23, 2026▼ -11.6%on this news
‘There’s a Tweed for That’: Canopy Growth Announces Tweed Brand Summer Campaign
Canopy Growth Corporation has announced a refresh of its Tweed brand, launching a national summer campaign titled 'There’s a Tweed for That.' The campaign aims to enhance consumer experience by introducing new window bags for Tweed's flower SKUs, allowing customers to see the product before purchase. This initiative is expected to strengthen Tweed's position in the Canadian cannabis market.
Read more →-CGC
Mar 16, 2026Canopy Growth Completes Acquisition of MTL Cannabis Canada's Leading Medical Cannabis Business By Revenue
Canopy Growth Corporation has successfully completed the acquisition of MTL Cannabis, enhancing its leadership position in the Canadian medical cannabis market. This acquisition is projected to yield significant operational synergies and supports the company's goal of attaining positive adjusted EBITDA by fiscal 2027. The arrangement sees the MTL management team integrate into Canopy Growth's operations, further bolstering its operational capabilities and product offerings in both domestic and international markets.
Read more →-CGC
Feb 6, 2026Canopy Growth Reports Third Quarter Fiscal 2026 Financial Results; Delivers double digit net revenue growth in Canada Cannabis contributing to a narrowing net loss; financial strength of $371M in cash and cash equivalent
Canopy Growth Corporation reported its financial results for Q3 FY2026, indicating a narrowing net loss and double-digit revenue growth in the Canadian cannabis market. The company highlighted a strong cash position and the successful execution of cost-saving measures, leading to improved performance. Despite these positive developments, Canopy Growth faced challenges in international markets, particularly in Europe, where sales decreased significantly. Additionally, the overall gross margin took a hit due to lower international revenues and changes in sales mix.
Read more →-CGC
Jan 8, 2026▲ +8.4%on this news
Canopy Growth Announces Strategic Recapitalization Transactions Strengthening Balance Sheet to Support Growth Strategy
Canopy Growth Corporation announced a strategic recapitalization involving a Term Loan of US$150 million and an exchange of convertible debentures. This maneuver is designed to extend the maturity of the company's existing debts to January 2031, enhancing liquidity and financial flexibility. The company anticipates having C$425 million in cash to support its long-term growth initiatives, signaling a drive to capitalise on opportunities in the evolving cannabis market.
Read more →About Canopy Growth Corporation
Headquarters1 HERSHEY DRIVE, SMITH FALLS, A6, K7A0A8
BIOPHARMAWATCH ELITE PLUS
Trade the next CGC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime